22 SKIN CARE A
3.0 2.5 2.0 1.5 1.0 0.5 0.0
I.s.
2.3% **
B 0 days A 28 days
7 6 5 4 3 2 1
0
Placebo Microcurrent device
2% Uplevity e-Lift peptide solution
C 2% Uplevity
e-Lift peptide solution
Female volunteer 13, 55 years old
Figure 6: A) Percentage of eyebrow distance mean increase (l.s. p<0.1, **p<0.01, vs. initial time, calculated using a paired Student´s t-test after checking the normality distribution by a Shapiro-Wilk test). B) Representative images showing eyebrow lifting effect after the use of a cream containing 2% Uplevity e-Lift peptide solution for 28 days C) Superimposed images showing the upper position of the eyebrow after active and placebo cream application versus initial time
was evaluated by determining the JC-1 red fluorescence intensity through confocal microscopy. As shown in Figure 5, the novel peptide
boosted the energy status of muscle cells in a dose dependent manner. Moreover, this induction was greater when compared to microcurrent stimulation. Overall, the novel peptide has demonstrated
to activate the molecular targets and the biological functions that take place after microcurrent stimulation at the dermis and muscle layers, which may help to provide an enhanced skin lifting and firming properties.
A ‘triorbital’ skin lifting effect A clinical test was carried out on 36 Caucasian female and male volunteers aged between 42
A B Female volunteer 9, 62 years old
Figure 7: A) Percentage of eyelid distance mean increase (*p<0.05, vs. initial time, calculated using a paired Student´s t-test after checking the normality distribution by a Shapiro-Wilk test). B) Representative images showing the eyelid lifting effect after 28 days of active cream application containing 2% Uplevity e-Lift peptide solution (upper panel) and after microcurrent device use (lower panel)
and 65 years old. These volunteers applied a cream containing 2% of the novel peptide solution or a placebo cream on the half upper face, twice day for 28 days, following a hemi- face design. A second group of ten volunteers used a commercial microcurrent device, once a day, five days a week, and applied a placebo cream, twice a day for 28 days. These volunteers were using the
microcurrent device daily on their upper face for around 10 minutes in each session. A ‘triorbital’ lift effect was quantified from the clinical study, which consisted of the supraorbital region (eyebrow and eyelid lift), the orbital region (crow´s feet lift) and the infraorbital region (upper cheek lift). Moreover, the anti-wrinkle efficacy was also evaluated in the crow´s feet region and
underneath the eye. The eyebrow lifting effect was calculated
from 2D images generated by Framescan. On each of these images, a horizontal line that goes from the middle point of the eyelashes to the end of the eyebrow arch was drawn. The longer the distance, the greater the
eyebrow lift. As shown in Figure 6, the active cream containing 2% of the novel peptide solution improved eyebrow lift after 28 days of product application by 2.3% in a statistically significant manner, when compared to initial time. Furthermore, the eyebrow lift efficacy
was very similar to the group using the microcurrent device. Finally, we superimposed the before and after images to visually evaluate the difference in the eyebrow
0 days vs. 28 days Placebo B 2% Uplevity
e-Lift peptide solution
Female volunteer 2, 46 years old Placebo 0 days
Microcurrent device
6.1% *
2% Uplevity e-Lift peptide solution
28 days
Figure 8: A) Example image of arrows representation over the skin surface, showing the direction and amount of the skin movement between the initial time and the final time of measurement. B) Lubrizol R&D Team´s computer vision approach to quantify the percentage lifting effect
PERSONAL CARE February 2024
www.personalcaremagazine.com
Eyelid distance mean increase (%)
Eyelid distance mean increase (%)
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80
